Results 131 to 140 of about 444,848 (367)

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential

open access: yesTherapeutic Advances in Medical Oncology, 2012
Based on preclinical data available in the RIP1-Tag2 transgenic mouse model, sunitinib is an inhibitor of angiogenesis in pancreatic neuroendocrine tumors blocking vascular endothelial growth factor receptors and platelet-derived growth factor receptors ...
Catherine Delbaldo   +3 more
doaj   +1 more source

Growth factors in idiopathic pulmonary fibrosis: relative roles [PDF]

open access: yes, 2001
Treatment of idiopathic pulmonary fibrosis patients has evolved very slowly; the fundamental approach of corticosteroids alone or in combination with other immunosuppressive agents has had little impact on long-term survival.
Allen, JT, Spiteri, MA
core   +3 more sources

Optimizing Angiopep‐2 Density on Polymeric Nanoparticles for Enhanced Blood–Brain Barrier Penetration and Glioblastoma Targeting: Insights From In Vitro and In Vivo Experiments

open access: yesAdvanced Functional Materials, EarlyView.
The Angiopep‐2 peptide density on polymeric nanoparticles significantly impacts blood–brain barrier (BBB) penetration. This study explores this nuanced relationship using various in vitro models and in vivo assays, revealing that dynamic models better predict BBB penetration.
Weisen Zhang   +9 more
wiley   +1 more source

Elevated expression of c-kit in small venous malformations of blue rubber bleb nevus syndrome

open access: yesRare Tumors, 2010
The blue rubber bleb nevus syndrome (BRBNS, syn. bean syndrome) is a rare disease characterized by multiple cutaneous and gastrointestinal venous malformations associated with severe bleeding.
Carolin Mogler   +5 more
doaj   +1 more source

Magnetically Guided Mechanoactive Mineralization Scaffolds for Enhanced Bone Regeneration

open access: yesAdvanced Functional Materials, EarlyView.
A 3D‐printed ‘rebar‐concrete’ inspired scaffold (PGS‐P@MGel) synergizes spontaneous biomineralization with magneto‐mechanical stimulation through PDA@Fe3O4‐embedded hydrogel. This dual biointerface activates Piezo1/β‐catenin/YAP mechanotransduction axis, enhancing BMSCs osteogenesis and angiogenesis simultaneously.
Xuran Guo   +10 more
wiley   +1 more source

Spreading of EGF Receptor Activity into EGF-free Regions and Molecular Therapies of Cancer [PDF]

open access: yesarXiv, 2008
The primary activation of the epidermal growth factor receptor (EGFR) has become a prominent target for molecular therapies against several forms of cancer. But despite considerable progress during the last years, many of its aspects remain poorly understood.
arxiv  

Paraneoplastic thrombocytosis in ovarian cancer [PDF]

open access: yes, 2012
<p>Background: The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear.</p> <p>Methods: We analyzed clinical data on 619 patients with epithelial ...
Akl EA   +35 more
core   +1 more source

Short‐Chain Fatty Acids Modulate Anti‐ROR1 CAR T‐Cell Function and Exhaustion in an Intestinal Adenocarcinoma‐on‐Chip Model

open access: yesAdvanced Healthcare Materials, EarlyView.
Short‐chain fatty acids modulate anti‐ROR1 chimeric antigen receptor (CAR) T‐cell function in an intestinal adenocarcinoma‐on‐chip model. Butyrate and propionate reduce cytotoxicity, cytokine release, and infiltration by inducing a regulatory T‐cell phenotype and T‐cell exhaustion via histone deacetylase inhibition.
Valentin D. Wegner   +5 more
wiley   +1 more source

Hypoxic Ventilatory Response in Platelet-Derived Growth Factor Receptor-β–Knockout Mice

open access: yesJournal of Pharmacological Sciences, 2009
.: The present study investigated whether the platelet-derived growth factor receptor (PDGFR)-β–mediated mechanisms are involved in the hypoxic ventilatory response through modulating the N-methyl-D-aspartate (NMDA) function.
Saori Tsunekawa   +4 more
doaj  

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib

open access: yesCase Reports in Oncology, 2018
Lenvatinib is an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, as well as platelet-derived growth factor receptor α, RET, and KIT.
Reiko Kimura-Tsuchiya   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy